UNC to Test Injectable Long-Acting Implant to Prevent HIV

Researchers at the University of North Carolina at Chapel Hill have received a three-year, $1.8 million grant from the National Institutes of Health to develop a new implantable drug delivery system for long-lasting HIV-prevention.

Scientists in the UNC School of Medicine’s Division of Infectious Diseases and the UNC Eshelman School of Pharmacy are developing an injectable drug delivery system that forms an implant that steadily releases anti-HIV medication over long periods of time.

The injectable formulation includes an anti-HIV drug, a polymer and a solvent. The three-compound liquid will solidify once injected under the skin. As the polymer slowly degrades, the drug is released. Efficacy of the new formulation to prevent HIV transmission will be evaluated using state of the art pre-clinical models developed at UNC.

Currently, a once-daily pill exists to prevent HIV infection. However, adherence to this daily regimen can be challenging for some people.

“This long-acting injectable formulation could provide a discrete and efficient method to protect against HIV infection and improve adherence, which is one of the major challenges of oral pre-exposure prophylaxis, or PrEP,” said Rahima Benhabbour, Ph.D., assistant professor in the UNC Eshelman School of Pharmacy and one of the study’s co-principal investigators. “The formulation is adaptable to a number of drugs alone or in combination and can be fine tuned to meet a targeted release regimen.”

Read more here..

Friday ID Conference: Dynamics and Clinical Relevance of Drug Resistant HIV

boucherThis talk is a part of our friday morning CFAR/IGHID Friday ID Conference Series.

“Dynamics and Clinical Relevance of Drug Resistant HIV; the end of the problem”
Speaker: Charles Boucher MD, PhD
Erasmus University Rotterdam, The Netherlands

September 12, 2014
8:30 – 9:30 a.m.
1131 Bioinformatics (first floor auditorium), UNC-CH Campus

Charles Boucher is Professor in the Department of Virology Erasmus Medical Center, Erasmus University Rotterdam, The Netherlands. Professor Boucher received his medical degree and PhD from the Faculty of Medicine of the University of Amsterdam, The Netherlands. He then furthered his studies in clinical microbiology and virology at the Academic Medical Center, Amsterdam and the University Medical Center Utrecht. He is the chairman of the European Society for Antiviral Resistance.

Professor Boucher is an organizer of international workshops, meetings and conferences, a consultant throughout Europe and the United States, a reviewer for scientific journals and co-chairman of several international committees. He is the author of numerous publications that have appeared in such journals as Science, The Lancet, Nature Medicine, Journal of Infectious Diseases and AIDS.

Refreshments will be served.

HIV DART 2014: “Frontiers in Drug Development for Antiretroviral Therapies”

HIVDART2014HIV DART 2014 Conference: “Frontiers in Drug Development for Antiretroviral Therapies”

December 9-12, 2014, Los Cabos, Mexico

The focus of HIV DART 2014 is to assemble clinicians, nurses, researchers and basic scientists together to advance our knowledge of the ongoing drug development processes in antiretroviral research. This conference will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community an increased understanding of the current and future challenges in therapeutics for HIV infection.

For more information, please visit the website.